{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:43:55Z","timestamp":1781207035651,"version":"3.54.1"},"reference-count":52,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Randomized controlled clinical trials and real-life observations indicate that less than 50% of patients with Crohn\u2019s disease (CD) or ulcerative colitis (UC) respond to vedolizumab, a humanized monoclonal antibody that blocks the \u03b14\u03b27 integrin. Since \u03b14\u03b27-expressing lymphocytes mainly infiltrate the left colon, we assessed whether localization of CD and UC influences vedolizumab-induced remission. One hundred and eighty-one patients (74 CD and 107 UC) receiving vedolizumab in 3 referral centers were retrospectively evaluated for clinical remission at week 14. Demographic and clinical characteristics were compared between remitters and non-responders, and multivariable multinomial analysis was performed to identify predictors of remission. Remission was achieved in 17 CD (23%) and 34 UC (32%) patients, respectively. In CD, localization of the lesions did not influence clinical remission. In UC, the remitters had more frequently a distal\/left-sided colitis (21\/34, 62%) as compared to the non-responders (9\/47, 19%), and extensive colitis was more frequent in the non-responders (38\/47, 81%) than in the remitters (13\/34, 38%). The multivariable multinomial analysis showed that distal\/left-sided colitis was associated with a higher probability of clinical remission while extensive colitis was inversely associated with induction of remission. Data indicate that UC patients with distal or left-sided colitis are more likely to achieve remission than patients with extensive colitis following vedolizumab treatment.<\/jats:p>","DOI":"10.3390\/jcm9020385","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T01:25:51Z","timestamp":1580693151000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab"],"prefix":"10.3390","volume":"9","author":[{"given":"Patrizio","family":"Scarozza","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Marafini","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0269","authenticated-orcid":false,"given":"Federica","family":"Laudisi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Troncone","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-9471","authenticated-orcid":false,"given":"Heike","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Friedrich-Alexander-University of Erlangen-Nuremberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Vincenzo","family":"Lenti","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-6551","authenticated-orcid":false,"given":"Stefania","family":"Costa","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Rocchetti","sequence":"additional","affiliation":[{"name":"Statistical Office, Superior Council of Judiciary, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"De Cristofaro","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salvatori","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Frezzati","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0302-8645","authenticated-orcid":false,"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Friedrich-Alexander-University of Erlangen-Nuremberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Neurath","sequence":"additional","affiliation":[{"name":"Department of Medicine 1, Friedrich-Alexander-University of Erlangen-Nuremberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11938-018-0175-1","article-title":"Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease","volume":"16","author":"Duijvestein","year":"2018","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaut.2017.07.004","article-title":"Novel therapeutic targets for inflammatory bowel disease","volume":"85","author":"Argollo","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.5009\/gnl16308","article-title":"Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics","volume":"11","author":"Katsanos","year":"2017","journal-title":"Gut Liver"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ibd\/izy327","article-title":"A State-of-the-Art Review of New Emerging Therapies for the Treatment of, I.B.D","volume":"25","author":"Christian","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","article-title":"Biologic agents for IBD: Practical insights","volume":"12","author":"Danese","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J. Pharm. Exp."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.153.2.517","article-title":"Expression and function of the MAdCAM\u22121 receptor, integrin alpha 4 beta 7, on human leukocytes","volume":"153","author":"Erle","year":"1994","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the \u03b14\u03b27 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment had failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ecco-jcc\/jjx143","article-title":"Vedolizumab in IBD-lessons from real-world experience; a systematic review and pooled analysis","volume":"12","author":"Engel","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2013a nationwide consecutive German cohort study","volume":"43","author":"Baumgart","year":"2016","journal-title":"Aliment Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00365521.2017.1304987","article-title":"Long-term effectiveness of vedolizumab in inflammatory bowel disease: A national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)","volume":"52","author":"Eriksson","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MIB.0000000000001039","article-title":"Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease-the Israeli real-world experience","volume":"23","author":"Kopylov","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","article-title":"Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice","volume":"10","author":"Vivio","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: Results from the US VICTORY consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41395-018-0162-0","article-title":"Vedolizumab for ulcerative colitis: Treatment outcomes from the VICTORY consortium","volume":"113","author":"Narula","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","first-page":"S601","article-title":"Long-term effectiveness and safety of vedolizumab in patients with Crohn\u2019s disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study","volume":"152","author":"Vermeire","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.14167","article-title":"One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: A prospective multicentre cohort study","volume":"46","author":"Amiot","year":"2017","journal-title":"Aliment Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apt.15294","article-title":"Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: A prospective multi-centre cohort study","volume":"50","author":"Amiot","year":"2019","journal-title":"Alim. Pharm. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/apt.13813","article-title":"Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease\u2014A prospective multicenter observational study","volume":"44","author":"Stallmach","year":"2016","journal-title":"Aliment. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic; radiologic; and histologic healing with vedolizumab in patients with active Crohn\u2019s disease","volume":"157","author":"Danese","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort","volume":"21","author":"Shelton","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s10620-017-4549-3","article-title":"Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab","volume":"62","author":"Allegretti","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.dld.2018.07.007","article-title":"A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study","volume":"50","author":"Lenti","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_31","first-page":"9","article-title":"Interrogating host immunity to predict treatment response in inflammatory bowel disease","volume":"17","author":"Atreya","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/apt.13243","article-title":"Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn\u2019s disease","volume":"42","author":"Rosario","year":"2015","journal-title":"Aliment Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure-efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn\u2019s disease","volume":"11","author":"Rosario","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"Williet","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/ecco-jcc\/jjz029","article-title":"Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis","volume":"13","author":"Pouillon","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MEG.0000000000001356","article-title":"Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance","volume":"31","author":"Liefferinckx","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ibd\/izy272","article-title":"Vedolizumab Drug Level Correlation with Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease","volume":"25","author":"Ramos","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients with Inflammatory Bowel Diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Pouillon, L., Vermeire, S., and Bossuyt, P. (2019). Vedolizumab trough level monitoring in inflammatory bowel disease: A state-of-the-art overview. Bmc. Med., 17.","DOI":"10.1186\/s12916-019-1323-8"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rath, T., Billmeier, U., Ferrazzi, F., Vieth, M., Ekici, A., Neurath, M.F., and Atreya, R. (2018). Effects of Anti-Integrin Treatment with Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. Front Immunol., 31.","DOI":"10.3389\/fimmu.2018.01700"},{"key":"ref_41","first-page":"304","article-title":"Should We Divide Crohn\u2019s Disease into Ileum-Dominant and Isolated Colonic Diseases?","volume":"19","author":"Dulai","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_42","first-page":"1191","article-title":"AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation","volume":"12","author":"Ichikawa","year":"2018","journal-title":"J. Crohns Coliti."},{"key":"ref_43","first-page":"288","article-title":"Altered expression of alpha E beta 7 integrin on intra-epithelial and lamina propria lymphocytes in patients with Crohn\u2019s disease","volume":"61","author":"Elewaut","year":"1998","journal-title":"Acta. Gastroenterol. Belg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/MIB.0000000000001029","article-title":"The \u03b14\u03b21 Homing Pathway Is Essential for Ileal Homing of Crohn\u2019s Disease Effector T Cells In Vivo","volume":"23","author":"Zundler","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn\u2019s Disease 2016: Part 1: Diagnosis and Medical Management","volume":"11","author":"Dignass","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s Disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/gutjnl-2018-317977","article-title":"Immune cell trafficking and retention in inflammatory bowel disease: Mechanistic insights and therapeutic advances","volume":"68","author":"Zundler","year":"2019","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"De Bruyn, J.R., Becker, M.A., Steenkamer, J., Wildenberg, M.E., Meijer, S.L., Buskens, C.J., Bemelman, W.A., L\u00f6wenberg, M., Ponsioen, C.Y., and van den Brink, G.R. (2018). Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn\u2019s disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190999"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Gisbert, J.P., and Chaparro, M. (2019). Predictors of primary response to biologic treatment (anti-TNF, vedolizumab and ustekinumab) in patients with inflammatory bowel disease: From basic science to clinical practice. J. Crohns Colitis.","DOI":"10.1093\/ecco-jcc\/jjz195"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kim, E.M., Randall, C., Betancourt, R., Keene, S., Lilly, A., Fowler, M., Dellon, E.S., and Herfarth, H.H. (2019). Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases. Inflamm. Bowel Dis., 21.","DOI":"10.1093\/ibd\/izz251"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:53:39Z","timestamp":1760172819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":52,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["jcm9020385"],"URL":"https:\/\/doi.org\/10.3390\/jcm9020385","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}